IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2017, compared with fiscal year ended March 31, 2016. Although the request refers to “2016 Q4,” this is an annual filing, not a quarterly report. The company develops phytocannabinoid-based therapies and also operated heavy-equipment rental and Malaysian project-management businesses. It exited its Hong Kong electronics business and ceased consolidating its China iron-ore business.
Key financial results
| Metric | FY2017 | FY2016 |
|---|---|---|
| Revenue | $580,372 | $6,366,550 |
| Cost of revenue | $362,135 | $5,523,256 |
| Gross profit / margin | $218,237 / approximately 37.6% | $843,294 / approximately 13.2% |
| SG&A | $1,875,344 | $2,702,753 |
| Operating loss | $2,054,385 | $2,905,710 |
| Net loss attributable to common stockholders | $1,867,260; loss per share $0.07 | $2,808,244; loss per share $0.17 |
| Net cash used in operating activities | $1,391,077 | $157,702 |
| Cash and cash equivalents at year-end | $538,029 | $1,490,693 |
| Total assets | $11,284,302 | $18,859,182 |
| Total liabilities | $3,934,017 | $4,911,111 |
Revenue fell about 91%, principally because electronics trading—an important FY2016 revenue source—was curtailed and exited. FY2017 revenue included $367,279 from Malaysian project management and Indian equipment rental, and $213,093 from electronics trading during the transition out. The company reported no revenue from its four cannabinoid product candidates.
Management cited lower SG&A and depreciation as factors in the reduced operating loss. Reported FY2017 net loss included investment-related gains and losses; the filing identifies a $227,472 gain on exiting Ironman, a $109,430 loss on exiting IGC International, and a $199,700 gain from the Midtown Partners investment. These items make the year’s reported loss less indicative of recurring operations.
Liquidity, debt and balance sheet
- Year-end working capital was approximately $2.29 million, with current assets of $3.58 million and current liabilities of $1.29 million. Current assets included a $1.88 million short-term investment; cash alone was $538,029.
- Cash declined by approximately $953,000 during the year. Operating cash outflow was $1.39 million, investing cash outflow $241,354, and financing cash inflow $707,564. Management separately cited adjusted, non-GAAP cash burn of approximately $1.37 million.
- Long-term liabilities included a $1.8 million Bricoleur note and $392,226 of other loans. The Bricoleur note had a stated July 31, 2016 maturity; the parties agreed to monthly interest payments in shares while discussing conversion or stock repayment of principal. The filing says there is no cash interest payable on that note.
- The company raised $642,164 through its at-the-market facility by issuing 1,697,021 shares. Weighted-average shares rose to 25.66 million from 16.39 million. The filing reports 28.27 million shares outstanding at March 31, 2017 and 30.57 million as of June 25, 2017.
Material changes and unusual items
- IGC International was exited, and Ironman was removed from consolidation after December 31, 2016. The company redeemed and retired approximately 2.63 million shares in connection with the exits and continued pursuing recovery of shares issued in the Ironman acquisition.
- In August 2016, IGC issued 4 million shares, valued at $1.88 million, for a 10% stake in Brilliant Hallmark, connected to a Malaysian hotel development. On April 3, 2017, it sold back the stake for the return and retirement of those shares; management did not expect a gain or loss.
- FY2017 revenue was highly concentrated: one Malaysian customer accounted for more than 42% of revenue. The filing also reports $430,689 of aged Cochin International Airport receivables outstanding for more than a year, carried at full value without impairment, and says collection timing remains uncertain.
- The company’s FY2017 cash-flow statement reports operating cash use of $1.39 million, while management’s adjusted cash-burn figure is a separate non-GAAP measure. These figures should not be treated as equivalent.
Outlook, risks and contingencies
Management’s strategy is to conduct human and veterinary trials on four cannabinoid product candidates, seek partners to market therapies, and develop additional products. No quantified revenue, earnings, cash-flow, or trial milestone guidance is provided. IGC stated that operating subsidiaries were at or near breakeven, but that corporate expenses drove much of the cash burn. It expects to raise capital to expand and has an ATM and Form S-3 available for potential financing.
- The four lead candidates target nausea/appetite issues, seizures in dogs and cats, Parkinson’s-related endpoints, and Alzheimer’s disease. They remain in development; the company had no customers or product revenue for them. Management noted that human FDA trials could take two to seven years and that U.S. testing involves DEA and controlled-substance restrictions. No DEA permits or FDA approvals were sought during FY2017.
- Risks include continued operating losses, limited liquidity and potential dilution from further equity issuance; regulatory and policy uncertainty for cannabis-related research; patent applications that may not result in granted patents; foreign-exchange and cross-border cash-transfer restrictions; customer concentration; and execution risks in early-stage drug development.
- The company disclosed ongoing efforts to recover value or obtain remedies relating to the Ironman acquisition and Midtown Partners agreement. Separately, it reported no material pending or threatened legal proceedings against IGC; the filing’s characterization and status of these matters merit review.
- The financial statements received an unqualified independent audit opinion. Management concluded disclosure controls and internal control over financial reporting were effective as of March 31, 2017. The filing nevertheless identifies accounting errors and foreign-subsidiary controls as risks.
Important facts for investors to verify
- Reconcile the sharp revenue decline, the electronics business’s exit and the continuing revenue contribution from that business during FY2017.
- Review cash availability and the maturity, repayment terms, share-interest arrangement and classification of the $1.8 million Bricoleur note.
- Assess collectability and timing for the aged $430,689 airport receivable and other construction-claim receivables.
- Confirm the completion and accounting treatment of the April 2017 Brilliant Hallmark share return, including the reduction in shares outstanding and removal of the investment.
- Check subsequent financing, share-count changes, trial progress, patent status and regulatory permissions; the filing provides no quantified operating guidance.